Eylea HD is a higher-dose version of the eye injection aflibercept, delivering 8 mg per injection compared to the original Eylea’s 2 mg. It’s FDA-approved to treat four serious retinal conditions and was designed to let patients go longer between injections while maintaining the same vision improvements. The drug is made by Regeneron Pharmaceuticals and is injected directly into the eye by a retinal specialist.
How Eylea HD Works
Several eye diseases share a common problem: abnormal blood vessels growing in the retina or leaking fluid into it, which damages vision. The protein most responsible for triggering this abnormal vessel growth is called VEGF (vascular endothelial growth factor). Eylea HD is a VEGF inhibitor, meaning it acts like a molecular sponge that binds to VEGF and prevents it from signaling blood vessels to grow or leak.
What sets aflibercept apart from other VEGF inhibitors is its range. It binds not only to the main culprit (VEGF-A) but also to two additional growth factors, VEGF-B and placental growth factor, that other treatments don’t block. This broader coverage is unique among approved VEGF inhibitors.
The “HD” in Eylea HD refers to the higher dose: 8 mg of aflibercept in a highly concentrated solution (114.3 mg/mL), compared to the original Eylea’s 2 mg in a 40 mg/mL solution. The injection volume is nearly the same, just 0.07 mL versus 0.05 mL. That fourfold increase in drug concentration is what allows the medication to remain active in the eye for a longer period, which is the real practical benefit for patients.
Conditions It Treats
Eylea HD is approved for four retinal conditions:
- Wet age-related macular degeneration (wet AMD), where abnormal blood vessels grow beneath the retina and leak fluid, causing central vision loss.
- Diabetic macular edema (DME), swelling in the center of the retina caused by leaking blood vessels in people with diabetes.
- Diabetic retinopathy (DR), the broader damage diabetes causes to blood vessels throughout the retina, even before noticeable vision loss.
- Macular edema following retinal vein occlusion (RVO), swelling that occurs when a vein in the retina becomes blocked.
The Injection Schedule
For most patients, the treatment pattern follows the same basic structure: a loading phase of monthly injections, then a transition to less frequent maintenance doses. The specifics vary slightly by condition.
For wet AMD and diabetic macular edema, the schedule starts with three monthly injections (one every four weeks), then shifts to maintenance injections every 8 to 16 weeks. After a year of good results, some patients can stretch that interval even further, to once every 20 weeks, or roughly every five months. That’s a significant reduction in office visits compared to the original Eylea, which typically required injections every 8 weeks on an ongoing basis.
For diabetic retinopathy, the loading phase is the same three monthly injections, but maintenance intervals range from every 8 to 12 weeks. For retinal vein occlusion, the loading phase may be three to five monthly injections, followed by maintenance every 8 weeks.
How It Compares to Standard Eylea
The primary advantage of Eylea HD over the original Eylea is fewer injections per year. In the PULSAR clinical trial, which studied wet AMD patients, those receiving Eylea HD every 12 or 16 weeks gained an average of 6.7 and 6.2 letters on a standard vision chart, respectively. Patients receiving the original 2 mg Eylea every 8 weeks gained 7.6 letters. These results were statistically non-inferior, meaning the higher dose at longer intervals delivered essentially equivalent vision improvement.
For patients, this translates to a meaningful quality-of-life difference. Instead of six or more injection visits per year, some people on Eylea HD may need only three to four, with the possibility of dropping to as few as two or three after the first year. Each visit involves numbing the eye, the injection itself, and a brief monitoring period, so fewer trips to the retina specialist saves real time and discomfort.
Common Side Effects
The side effects of Eylea HD are similar to those of the original formulation and of eye injections in general. The most common reactions, occurring in 3% or more of patients in clinical trials, include cataracts, small bleeds on the white of the eye (conjunctival hemorrhage), minor corneal surface scratches, increased eye pressure, eye discomfort or pain, retinal bleeding, blurred vision, vitreous detachment, and floaters.
Increased eye pressure is one side effect that clinicians watch for specifically. In clinical trials, it occurred in 1% to 7% of patients depending on the study and dosing schedule. A temporary spike in eye pressure can happen within 60 minutes of any intravitreal injection, including Eylea HD, which is why your eye doctor typically checks pressure before you leave the office. Inflammation inside the eye was less common, occurring in 1% to 2% of patients across trials.
Most of these side effects are mild and resolve on their own. The more serious risks, like infection inside the eye or retinal detachment, are rare but are inherent to any procedure involving a needle in the eye, not specific to this drug.
What the Injection Experience Looks Like
If you’ve been told you need Eylea HD, the actual appointment is typically quick. Your eye will be numbed with drops, and the area will be cleaned with an antiseptic solution. The injection itself takes only a few seconds. You’ll likely feel pressure but not sharp pain. Afterward, you may notice floaters or mild irritation for a day or two. Vision can be slightly blurry immediately after but usually clears within hours.
The first three months require monthly visits for the loading doses. After that, your retina specialist will assess how your eye is responding and set a maintenance schedule. If things are going well, the intervals between injections will gradually lengthen. That decision is based on imaging of your retina and your visual acuity at each follow-up.